Clinical experience with the combined contraceptive vaginal ring in Switzerland, including a subgroup analysis of previous hormonal contraceptive use

European Journal of Contraception and Reproductive Health Care

Volumn 15, Issue 6, 2010, Pages 413-422

  Merki Feld, Gabriele S ^a   Hund, Martin ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Roche Diagnostics Ltd   (Switzerland)

Author keywords

Clinical experience; Dysmenorrhoea; Menstrual headache; PMS; Satisfaction; Starter; Switcher; Vaginal ring

Indexed keywords

ETHINYLESTRADIOL PLUS ETONOGESTREL; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; BODY WEIGHT; CONDOM; DISEASE SEVERITY; DRUG RESPONSE; DRUG USE; DYSMENORRHEA; FEMALE; FOLLOW UP; HEADACHE; HORMONAL CONTRACEPTION; HUMAN; INTRAUTERINE DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; MENSTRUATION; MENSTRUATION DISORDER; PATIENT SATISFACTION; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; QUESTIONNAIRE; SWITZERLAND; TREATMENT OUTCOME; VAGINA RING; VAGINAL DISCOMFORT;

ADOLESCENT; ADULT; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVE DEVICES, FEMALE; DESOGESTREL; DRUG COMBINATIONS; ETHINYL ESTRADIOL; FEMALE; HUMANS; MENSTRUATION DISTURBANCES; MIDDLE AGED; OBSERVATION; OVULATION; PATIENT SATISFACTION; SWITZERLAND; YOUNG ADULT;

EID: 78649353442     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.3109/13625187.2010.524717     Document Type: Article

References (20)

1. Timmer CJ, Mulders TM. Pharmacokinetics of etono-gestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet 2000;39:233-42.
2. van den Heuvel M, van Bragt A, Alnabawy A, et al. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: The vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005;72:168-74.
3. Novák A, de la Loge C, Abetz L, et al. The combined contraceptive vaginal ring, NuvaRing: An international study of user acceptability. Contraception 2003;67:187-94.
4. Roumen FJ. Review of the combined contraceptive vaginal ring, NuvaRing. Ther Clin Risk Manag 2008;4:441-51.
5. 1). J Fam Plann Reprod Health Care 2008;34:247-50.
6. Mulders TM, Dieben TO. Use of the novel combined contraceptive vaginal ring for ovulation inhibition. Fertil Steril 2001;75:865-70.
7. Oddsson K, Leifels-Fischer B, Wiel-Masson D, et al. Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 mg ethinylestradiol and 150 mg levonorgestrel: A randomized trial. Hum Reprod 2005;20:557-62.
8. Milsom I, Lete I, Bjertnaes A, et al. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 mg ethinyl estradiol and 3 mg drospirenone. Hum Reprod 2006;21:2304-11.
9. Bjarnadóttir RI, Tuppurainen M, Killick SR. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ ethinyl estradiol. Am J Obstet Gynecol 2002;186:389-95.
10. Schering-Plough News Release. Schering-Plough announces imperfect contraceptive use impacts women's emotional well-being. 16 April 2008. Accessed 28 August 2010 from: http://www.merck.com/news-room/news-release-archive/ schering-plough-news-arch ive/all/releaseid1130685.html
11. Roumen FJ, op ten Berg MM, Hoomans EH. The combined contraceptive vaginal ring (NuvaRing): First experience in daily clinical practice in The Netherlands. Eur J Contracept Reprod Health Care 2006;11:14-22.
12. Merki-Feld GS, Hund M. Clinical experience with NuvaRing in daily practice in Switzerland: Cycle control and acceptability among women of all reproductive ages. Eur J Contracept Reprod Health Care 2007;12:240-7.
13. Brucker C, Karck U, Merkle E. Cycle control, tolerability, efficacy and acceptability of the vaginal contraceptive ring, NuvaRing: Results of clinical experience in Germany. Eur J Contracept Reprod Health Care 2008;13:31-8.
14. Yonkers KA, O'Brien PM, Eriksson E. Premenstrual syndrome. Lancet 2008;371:1200-10.
15. Gallo MF, Nanda K, Grimes DA, et al. 20 mcg versus 420 mcg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev 2008;8:CD003989.
16. Ornstein RM, Fisher MM. Hormonal contraception in adolescents: Special considerations. Paediatr Drugs 2006;8:25-45.
17. Clayton AH. Symptoms related to the menstrual cycle: Diagnosis, prevalence, and treatment. J Psychiatr Pract 2008;14:13-21.
18. The ESHRE Capri Workshop Group. Noncontracep-tive health benefits of combined oral contraception. Hum Reprod Update 2005;11:513-25.
19. Usman SB, Indusekhar R, O'Brien S. Hormonal management of premenstrual syndrome. Best Pract Res Clin Obstet Gynaecol 2008;22:251-60.
20. Allais G, Castagnoli Gabellari I, De Lorenzo C, et al. Menstrual migraine: Clinical and therapeutical aspects. Expert Rev Neurother 2007;7:1105-20.